Myriad Genetics reports preliminary Q4 rev $209-211M, FY2025 adj EPS guidance $0.07-0.11

MYRIAD GENETICS INC

2024-FY EPS reported -$1.41 revenue$837,600,000

Q4 2024 preliminary revenue $209-211M (+6-7% YoY); GAAP diluted loss $(0.72)-(0.62)/share; adj EPS $0.03-$0.04.
Full year 2024 preliminary revenue $836-838M (+11% YoY); GAAP loss $(1.66)-(1.56)/share; adj EPS $0.14-$0.15.
Cash and equivalents $102M as of Dec 31, 2024, up $2M from Q3.
FY2025 guidance: revenue $840-860M (0-3% growth); adj EPS $0.07-$0.11; adj EBITDA $25-35M.
FY2025 guidance reflects impact from UnitedHealthcare coverage changes and EndoPredict divestiture.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.